osthol has been researched along with Cancer of Cervix in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, P; Huang, M; Huang, Q; Mei, J; Pan, L; Wang, D; Zhang, X | 1 |
| Che, Y; Li, J; Li, Z; Wang, S; Yan, Y; Zou, K; Zou, L | 1 |
| Li, X; Liu, Z; Su, J; Zhang, F | 1 |
3 other study(ies) available for osthol and Cancer of Cervix
| Article | Year |
|---|---|
DCLK1 might be a therapeutic target of osthole against cervical cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Coumarins; Doublecortin-Like Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Serine-Threonine Kinases; Uterine Cervical Neoplasms | 2021 |
Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NF‑κB signaling.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cnidium; Coumarins; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Female; Humans; NF-kappa B; Radiation Tolerance; Signal Transduction; Uterine Cervical Neoplasms | 2018 |
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Coumarins; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Mice; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |